Replies to post #4059 on BioCurex, Inc.(fka BOCX)

[Headache]

Another somewhat positive point, which I'm not sure has ever been mentioned on this board, is that a general RECAF-based test would not compete directly with more specific tests. Instead, it would drive demand for more specific tests, creating opportunities to partner with the owners of other diagnostic technology, rather than compete with them.

[dakota]

Sorry mysscat, guess I was just confused at the time. Thanks for the reply.